PTC Therapeutics Financial Ratios
NASDAQ: PTCTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
64.70+2.14 (+3.42%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
PTC Therapeutics ratio analysis
PTC Therapeutics earned a net margin of 39.4% in FY 2025, up from -45.0% a year earlier. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
PTC Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 9.86 | — | — | — | — | — | — | — | — | — |
| Price / sales | 3.53 | 4.43 | 2.20 | 3.92 | 5.21 | 10.58 | 9.26 | 6.31 | 3.36 | 4.49 |
| Price / book | — | — | — | — | 1,951.79 | 8.36 | 4.78 | 4.76 | 4.18 | 3.11 |
| Gross margin | — | — | — | — | — | — | 96.0% | 95.2% | 97.6% | 100.0% |
| Operating margin | 50.1% | -37.5% | -46.9% | -64.0% | -69.5% | -113.4% | -78.6% | -43.7% | -33.1% | -159.7% |
| Net margin | 39.4% | -45.0% | -66.8% | -80.0% | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% |
| Free cash flow margin | 40.6% | -14.2% | -19.9% | -55.6% | -51.9% | -55.7% | -36.6% | -13.1% | -6.8% | -127.4% |
| Return on equity (ROE) | — | — | — | — | -36,432.6% | -90.9% | -42.3% | -36.5% | -50.5% | -118.8% |
| Return on assets (ROA) | 23.5% | -21.3% | -33.1% | -32.8% | -27.0% | -19.8% | -15.5% | -11.4% | -20.2% | -52.8% |
| Debt / equity | — | — | — | — | 300.02 | 0.64 | 0.53 | 0.44 | 0.93 | 0.82 |
| Current ratio | 2.35 | 2.35 | 2.02 | 1.71 | 1.87 | 4.44 | 3.30 | 1.92 | 3.04 | 5.27 |
| Revenue growth | 114.5% | -14.0% | 34.2% | 29.7% | 41.4% | 24.0% | 16.0% | 36.2% | 135.0% | 124.9% |